Document text
Principal Investigator: Mark Morris Davis
Organization: STANFORD UNIVERSITY
Fiscal Year: 2024
Award: $2,200,798
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY
Influenza and SARS-CoV-2 are respiratory viruses that represent a continual threat to the health of many
Americans, and will likely account for 100,000 deaths and many times that number of hospitalizations in the US
alone each year. The available vaccines are inadequate, with the recent flu vaccine estimated to be only 40%
effective and while the RNA vaccines for SARS-CoV-2 have been remarkable at preventing severe illness or death,
they do not prevent reinfection in many people. Many with pre-existing conditions or immune deficiencies (e.g.,
obesity, diabetes) are vulnerable, which leads to suppressed response to vaccine or increased risk of severe
outcome upon infection. Thus, the need to understand and improve both vaccines and the response to them is
urgent. The Stanford CCHI has been a leader in understanding influenza vaccination and infection, and very quickly
developed complementary expertise during the pandemic, making great strides in both understanding SARS-CoV-
2 infection and vaccine responses, and also in developing new technologies that promise even greater advances.
These range from Dr. Wang’s insights in the effects of antibody glycosylation and lung inflammation, to Dr. Barnes
seminal work on the structures of antibodies to SARS-CoV-2 antigens. Work that Dr. Barnes will carry further by
designing and testing novel flu and SARS-Cov-2 antigen constructs. Dr. Khatri has also developed bioinformatic
methods that have revealed conserved gene signatures regarding the immune response to viruses, and which he
will use to define the cells and mechanisms that underlie these signatures. The clinical core under Dr. Chinthrajah
will recruit and vaccinate obese and diabetic patients at risk for severe COVID and Influenza illness, and the results
will be analyzed by Dr. Wang and also by the Human Immune Monitoring core under Dr. Maecker. Dr. Davis will
head the Technology Development project which will continue his development of immune organoids and the use
of spleen organoids particularly to characterize both existing and novel vaccine responses, and also attempt to
reconstruct immune responses to vaccination and infection using skin and lung organoids from the same donors.
Organoid responses to vaccination or infection will be validated against data in human subjects using our collection
of influenza and SARS-CoV-2 specific T and B cell probes, as well as through TCR and BCR sequence analysis.
Organoid processing and banking will be handled by the clinical core and all projects will make use of this resource,
which will be especially useful in testing particular immunogens for their ability to make the desired antibodies, or
the use of gene editing to identify key loci mediating particular effects. Immune organoids and the networks we
propose to create will give us the ability to test hypotheses and define mechanisms in an entirely human system.
The overall theme of this submission is to continue our efforts to understand Influenza and SARS-CoV-2
vaccination and infection using a broad range of approaches, integrating molecular, structural and bioinformatic
methods, in vivo with unique cohorts and in vitro with organoids.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><21+ years old><Acceleration><Adult><Adult Human><American><Antibodies><Antigens><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Bio-Informatics><Bioinformatics><Blood><Blood Reticuloendothelial System><Blood Sample><Blood specimen><Body Tissues><COVID crisis><COVID epidemic><COVID infected patient><COVID pandemic><COVID patient><COVID positive patient><COVID-19 antibody><COVID-19 antigen><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infected patient><COVID-19 infection><COVID-19 pandemic><COVID-19 patient><COVID-19 period><COVID-19 positive patient><COVID-19 public health crisis><COVID-19 vaccination><COVID-19 vaccine><COVID-19 virus><COVID-19 virus infection><COVID-19 years><COVID19 infection><COVID19 patient><COVID19 positive patient><COVID19 virus><Cell Body><Cells><Cessation of life><Clinical><CoV-2><CoV2><Collection><Communities><Data><Death><Development><Diabetes Mellitus><Dysfunction><Explosion><Flu vaccination><Functional disorder><General Population><General Public><Genes><Government><Grippe><Head><Health><Home><Hospital Admission><Hospitalization><Human><Immune><Immune Monitoring><Immune response><Immune system><Immunes><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunomonitoring><In Vitro><Individual><Infection><Influenza><Influenza Vaccines><Influenza immunization><Influenza vaccination><Lung><Lung Inflammation><Lung Respiratory System><Lung infections><Mediating><Metabolic Glycosylation><Methods><Modeling><Modern Man><Molecular><Non obese><Nonobese><Obesity><Organoids><Outcome><Paper><Pathway interactions><Persons><Phenotype><Physiopathology><Pneumonitis><Prophylactic vaccination against influenza><Publishing><Pulmonary Inflammation><RNA vaccine><RNA-based vaccine><Research Resources><Resources><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 antibody><SARS-CoV-2 antigen><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 vaccination><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SEQ-AN><Sampling><Seminal><Sequence Analyses><Sequence Analysis><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Skin><Spleen><Spleen Reticuloendothelial System><Structure><System><T-Cells><T-Lymphocyte><Technology><Testing><Tissues><Twin Multiple Birth><Twins><Vaccinated><Vaccination><Vaccines><Virus><Work><Wuhan coronavirus><access to vaccination><access to vaccines><adiposity><adulthood><antibody against COVID-19><antibody against SARS-CoV-2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody to COVID-19><antibody to SARS-CoV-2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><cohort><coronavirus disease 2019 antibody><coronavirus disease 2019 antigen><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 public health crisis><coronavirus disease 2019 vaccination><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 patient><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus patient><corpulence><design><designing><developmental><diabetes><diabetic patient><flu><flu immunisation><flu infection><flu vaccine><flu virus infection><flu virus vaccine><gene conservation><gene signatures><genetic signature><glycosylation><hCoV19><high risk group><high risk individual><high risk people><high risk population><homes><host response><human subject><hypoimmunity><immune deficiency><immune response to vaccination><immune response to vaccines><immune system response><immunodeficiency><immunogen><immunoresponse><improved><in vitro Model><in vivo><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with flu><infected with flu virus><infected with influenza><infected with influenza virus><infected with severe acute respiratory syndrome coronavirus 2><influenza infection><influenza virus infection><influenza virus vaccination><influenza virus vaccine><insight><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><mRNA vaccine><mRNA-based vaccine><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><new technology><new vaccines><next generation vaccines><novel><novel technologies><novel vaccines><obese patients><pandemic><pandemic disease><pathogen><pathophysiology><pathway><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><patients with obesity><prevent><preventing><pulmonary><pulmonary infections><recruit><respiratory virus><response><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 antigen><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><tech development><technology development><thymus derived lymphocyte><trend><vaccinate against COVID-19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccination access><vaccination against COVID-19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccination against influenza><vaccination availability><vaccine access><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine against flu><vaccine against influenza><vaccine associated immune response><vaccine availability><vaccine candidate><vaccine candidates against SARS-CoV-2><vaccine efficacy><vaccine for novel coronavirus><vaccine immune response><vaccine immunogenicity><vaccine induced immune response><vaccine response><vaccine responsiveness><vaccine-induced response><vaccines preventing COVID><vaccines to prevent COVID>